This Article Full Text (PDF) All Versions of this Article: 1076029607308873v1 1076029607308873v2 15/4/454    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Scopus Google Scholar Articles by Turna, H. Articles by Balci, H. PubMed PubMed Citation Articles by Turna, H. Articles by Balci, H. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Bleeding Disorders Cancer Social Bookmarking                         What's this?

Is There Any Effect of Tumor Burden on Hemostatic Parameters in Cancer Patients? A Case—Control Study of Hemostatic Abnormalities and Anticardiolipin Antibodies in Solid Tumors

Department of Medical Oncology Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Mustafa Ozguroglu, MD

Department of Medical Oncology Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey, ozguroglu{at}gmail.com

Murat Bolayirli, MD

Fikret Biyal Central Research Laboratory, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Timur Orhanoglu, MD

Department of Medical Oncology Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Huriye Balci, PhD

Department of Medical Oncology Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey

Hemostatic complications are one of the leading causes of mortality in cancer patients. In the present study, we assessed the hemostatic parameters and anticardiolipin antibodies in patients with solid tumors (n = 104) and healthy controls (n = 25) and also find out whether the abnormalities in these hemostatic parameters vary related to tumor burden. Prothrombin time, activated partial thromboplastine time, D-dimer, and fibrinogen as hemostatic parameters were determined by photo-optometric clot detection system, and serum anticardiolipin levels were measured by enzyme-linked immunosorbent assay. The plasma levels of fibrinogen, D-dimer, and serum anticardiolipin IgM levels in cancer patients were significantly higher compared with those in controls (P < .001, P = .001, and P = .01, respectively). Only fibrinogen levels were significantly higher in metastatic group than nonmetastatic group (P < .001 ). Hemostatic abnormalities that are detected in asymptomatic cancer patients may not give any clue about tumor burden or stage of the cancer patients.

Key Words: coagulation • cancer • anticardiolipin antibodies • fibrinogen • D-dimer

This version was published on August 1, 2009

Clinical and Applied Thrombosis/Hemostasis, Vol. 15, No. 4, 454-457 (2009)
DOI: 10.1177/1076029607308873


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?